-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $42

Benzinga·07/22/2025 12:57:25
Listen to the news
Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $40 to $42.